Adenosine (10 Ϫ4 M) stimulated OMDVR cAMP production greater than threefold. NO synthase blockade with N G -nitro-L-arginine methyl ester and N G -monomethyl-L-arginine (10 Ϫ4 M) did not affect adenosine vasodilation. Adenosine induced endothelial cytoplasmic calcium transients that were small. Indomethacin (10 Ϫ6 M) reversed adenonsineinduced dilation of OMDVR preconstricted with ANG II, endothelin, 4-bromo-calcium ionophore A23187, or carbocyclic thromboxane A 2 . In contrast, selective A 2 -receptor activation dilated endothelin-preconstricted OMDVR even in the presence of indomethacin. We conclude that OMDVR vasodilation by adenosine involves cAMP and COX but not NO. COX blockade does not fully inhibit selective A 2 receptormediated OMDVR dilation. rat; microcirculation; microperfusion; fura 2; 8-cyclopentyl-1,3-dipropylxanthine; 2-p- [2-carboxyethyl] phenethyl-amino-5Ј-N-ethylcarboxamido-adenosine ADENOSINE EXERTS HETEROGENEOUS effects on blood flow to different regions of the kidney. It reduces blood flow to the cortex, probably through constriction of afferent arterioles (3, 12, 23, 38) . In contrast, adenosine acts as a vasodilator in the renal medulla where low oxygen tensions favor its formation (3, 20) . On the basis of these considerations, it has been hypothesized that extravascular adenosine generation might serve to dilate local resistance vessels, thereby enhancing oxygen delivery as a defense against ischemic insult (3, 10, 14, 31) . The tubular-vascular relationships in the juxtamedullary region of the cortex and outer medulla imply that the vasodilatory effects of adenosine must occur along the resistance vessels of juxtamedullary glomeruli (21) or in outer medullary descending vasa recta (OMDVR) (26) . The parallel arrangement of OMDVR within vascular bundles of the inner stripe of the outer medulla suggests that they are particularly likely to be the target for regulation of the distribution of blood flow to the outer vs. inner medulla of the kidney. Consistent with this notion, adenosine A 1 -and A 2 (A 2a and A 2b )-receptor expression has been identified in OMDVR both by RT-PCR and pharmacological studies (14, 31) .
Several signaling mechanisms have been proposed to mediate adenosine A 2 receptor-induced relaxation of smooth muscle cells. These include stimulation of cAMP production (8, 15) , inhibition of calcium influx (11, 28) , and membrane hyperpolarization (29, 30) . In addition to the proposed effects on smooth muscle, there are reports that the vasodilatory effect of adenosine depends on an intact endothelium (34, 39) and the production of nitric oxide (NO) (1, 2, 9, 18, 19) . Renal hemodynamic studies favor mediation of vasoconstriction via A 1 receptors (4, 22) and NO-induced vasodilation through A 2b receptors (19) . Prostaglandins may play a role in the vasodilatory response to adenosine. Indomethacin does not block adenosine A 1 receptor-mediated vasoconstriction (4, 6); however, the secondary increase in renal blood flow caused by adenosine A 2 -receptor stimulation is attenuated by cyclooxygenase (COX) inhibition (6) .
In this study, we tested the hypothesis that adenosine vasodilates OMDVR through events that lead to stimulation of adenyl cyclase and that this process involves signaling through NO or prostaglandins. The results show the importance of cAMP and COX but fail to identify a role for NO.
METHODS
In vitro microperfusion. Details of the methods employed to perfuse OMDVR and documents of their contractility have been published (24-26, 31, 32) . In brief, young female Sprague-Dawley rats (Harlan) were anesthetized by intraperitoneal injection of thiopental sodium (50 mg/kg) after which the kidneys were harvested, sliced, and placed into cold (4°C) HEPES dissection buffer (in mM: 5 HEPES, 140 NaCl, 10 Na acetate, 
Measurement of endothelial intracellular calcium. OMDVR were loaded with the Ca 2ϩ -sensitive fluorescent indicator fura 2 by exposure to bath containing 2 M fura 2-AM ester (Molecular Probes). At the time the bath was exchanged to contain fura 2-AM, the feedback controller was turned on, gradually warming the vessel to 37°C over ϳ5 min. Total loading time was 20 min. Under these conditions, we have shown that fura 2 preferentially loads into endothelial cells with little or no fluorescent emission originating from the pericytes (25) . For measurement of intracellular calcium concentration ([Ca 2ϩ ] i ), fura 2-loaded OMDVR were excited with the use of 350-or 380-nm dual wavelength combinations. The background-subtracted ratio of fluorescent emission (R 350/380 ) was calculated for conversion to the equivalent [Ca 2ϩ ] i assuming a dissociation constant of 224 nM. R max and R min were measured as previously described by exposing vessels to buffer containing 5 mM CaCl 2 or 0 CaCl 2 and 0.5 mM EGTA, respectively, along with 10 M 4-bromo-calcium ionophore A23187 (4-Br A23187) (25) . A photon-counting photomultiplier assembly (PMT) was employed to measure fluorescent emission at 510 nm. Light for excitation of fura 2 was provided from a 75-W xenon arc lamp and directed through a computer-controlled monochrometer (PTI). OMDVR were observed through a 1.3 numerical aperture, Nikon CF fluor ϫ40 oil-immersion objective, and the fluorescent emission from fura 2 was isolated with a 510WB40 filter (Omega Optical).
Enzyme immunoassay for cAMP. The second messenger, cAMP, was measured in microdissected OMDVR by enzymeimmunoassay kit (Assay Designs). Rats were decapitated, and the left kidney was prepared for perfusion by ligating the aorta above the left renal artery. The kidney was perfused over 10 min through the aorta below the left renal artery with 10 ml ice-cold dissection solution followed by 10 ml dissection solution containing 1 mg/ml collagenase B (Boehringer Mannheim) at 37°C. The kidney was removed, decapsulated, sliced coronally, and digested for an additional 60-90 min by shaking in 1 mg/ml collagenase B at 37°C. The slices were then rinsed and maintained at 4°C during dissection. OMDVR segments were harvested until Ͼ30-mm cumulative length was obtained. These vessels were transferred in 10 l dissection solution to a 1.5-ml centrifuge tube containing a phosphodiesterase inhibitor (Ro-20-1724, 10 Ϫ4 M) in 20 l dissection solution (total 30 l). Blanks without OMDVR were also collected from the dissection solution. Tubes were preincubated in a 37°C water bath for 5 min. After 5-min preincubation at 37°C, 30 l of dissection buffer containing vehicle, adenosine (10 Ϫ4 M), or forskolin (10 Ϫ4 M) were added for 20 min at 37°C. Cross-reactivity of agonists with kit cAMP antibody was tested and found to be insignificant. Incubations were terminated by the addition of 60 l ice-cold 0.1 M HCl (total 120 l). Tubes were vortexed and centrifuged at 9,000 rpm for 6 min. Onehundred microliters of supernatant were collected and stored at Ϫ20°C until assay. Samples were assayed according to the acetylated cAMP-kit protocol.
Reagents .
, forskolin (7␤-acetoxy-1␣,6␤,9␣-trihydroxy-8,13-epoxy-labd-14-en-11-one), and SQ-22536 (9-(tetrahydro-2-furanyl)-9 H-purin-6-amine) were purchased from Research Biochemicals International. Ro-20-1724, 4-Br A23187, and indomethacin were dissolved in ethanol. Forskolin was dissolved in anhydrous DMSO. All other agents were dissolved in deionized water. After solubilization, pharmacological agents were stored at Ϫ20°C in small aliquots of 10 Ϫ2 to 10 Ϫ5 M. Aliquots were thawed and diluted at least 1,000-fold on the day of the experiment. Unused portions were discarded.
Statistical analysis. Experimental results are reported as means Ϯ SE. Statistical comparisons employ a paired t-test or repeated-measures ANOVA as appropriate. For ANOVA, significance was determined by the Student-Newman-Keuls test. P values Ͻ0.05 are considered significant.
RESULTS

Signaling of adenosine in OMDVR via cAMP.
We first tested the hypothesis that stimulation with adenosine or cAMP would vasodilate OMDVR. Both the cell-permeant analog 8-BrcAMP and adenosine dilated ANG II (10 Ϫ9 M)-preconstricted vessels in a concentration-dependent manner (Fig. 1A) . Vasodilation by adenosine (10 Ϫ10 -10 Ϫ4 M) or 8-BrcAMP was readily reversible (Fig. 1B) . Furthermore, in the absence of ANG II, neither sham exchange nor 8-BrcAMP induced significant OMDVR vasoconstriction (Fig. 1C) .
The results in Fig. 1 , A-C support the possibility that cAMP could be a secondary mediator to induce vasodilation, but they do not establish a causal relationship between adenosine and signaling via the cAMP pathway. In view of this, we next tested the hypothesis that adenosine requires stimulation of adenyl cyclase to vasodilate OMDVR. Vessels were constricted with ANG II (10 Ϫ9 M) and then vasodilated with adenosine (10 Ϫ6 M). Subsequent addition of the adenyl cyclase inhibitor SQ-22536 (10 Ϫ6 M) readily reversed adeno-sine-induced vasodilation (Fig. 2) . In a separate series of experiments (n ϭ 7), the lack of effect of SQ-22536 on baseline OMDVR was verified. Internal diameters averaged 11.9 Ϯ 0.6, 11.9 Ϯ 0.8, and 12.1 Ϯ 0.7 m before, during, and after 5-min application of SQ-22536 (10 Ϫ6 M).
To further establish the existence of signaling through the cAMP pathway, we directly measured cAMP generation by isolated vessels in response to adenosine. Microdissected OMDVR were exposed to vehicle, adenosine, or forskolin for 20 min. Adenosine (10 Ϫ4 M) increased cAMP generation to 326% of control values, and forskolin increased cAMP 20-fold (Fig. 3) . Fig. 1 . Vasoactive effects of 8-bromoadenosine 3Ј,5Ј-cyclic monophosphate (8-BrcAMP) and adenosine (ADO) on outer medullary descending vasa recta (OMDVR). A: OMDVR were preconstricted with abluminal ANG II (10 Ϫ9 M) for 10 min after which either ADO (E, n ϭ 9) or 8-BrcAMP (ᮀ, n ϭ 7) was added in log molar increments. ADO, in concentrations Ն10 Ϫ6 M, dilated ANG II-preconstricted vessels (*P Ͻ 0.05 vs. sham exchange). Sham exchange of the bath with ANG II alone (F, n ϭ 7) did not induce vasodilation. B: the vasodilatory effects of ADO (10 Ϫ6 M, n ϭ 12) and 8-BrcAMP (n ϭ 11) were reversible (*P Ͻ 0.05 vs. first ANG II application; #P Ͻ 0.05 recovery period vs. ANG II ϩ agonist). C: neither 8-BrcAMP (E, n ϭ 6) nor vehicle (F, n ϭ 8) induced significant vasoconstriction. NO as a possible mediator of adenosine-induced vasodilation. Having established that cAMP is generated in response to adenosine and is required for vasodilation, we next tested the hypothesis that adenosineinduced vasodilation is mediated through NO generation. Vessels were constricted with ANG II (10 Ϫ9 M) and then dilated with adenosine in either the presence or absence of NO synthase (NOS) inhibitors. Neither L-NMMA nor L-NAME (10 Ϫ4 M) blocked the effect of adenosine (10 Ϫ6 M) to dilate ANG II-preconstricted OMDVR, implying that NO generation is unlikely to contribute to adenosine-induced vasodilation (Fig. 4) .
To further establish that calcium-sensitive isoforms of NOS are unlikely to be activated by adenosine, we next compared the endothelial [Ca 2ϩ ] i responses of adenosine with that induced by bradykinin. Interestingly, responses were consistently observed with adenosine at either 10 Ϫ9 or 10 Ϫ5 M, but these were much smaller than that observed with the true endotheliumdependent vasodilator bradykinin (Fig. 5) .
Prostaglandins as mediators of adenosine-induced vasodilation.
To test the hypothesis that prostaglandins mediate the response of OMDVR to adenosine, we examined the effect of COX inhibition with indomethacin on vasodilation. The effects were complicated by the observation that ANG II preconstriction is itself substantially inhibited by indomethacin (10 Ϫ6 M) (Fig.  6 ). This implies that vasoconstrictor prostaglandins such as thromboxanes are likely to be responsible for ANG II-induced OMDVR vasoconstriction. Nonetheless, consistent with the notion that adenosine-induced vasodilation requires COX product(s) (e.g., Figs. 1, 2, and 4), adenosine acted as a vasoconstrictor rather than as a vasodilator in the presence of indomethacin (Fig. 6) . The potentiation of adenosine-induced vasoconstriction by COX inhibition has been substantiated by several reports (27, 33) .
We next verified that adenosine-induced vasodilation of OMDVR is prostaglandin dependent when vasoconstriction is induced by other agents. Specifically, we tested vessels preconstricted with the thromboxane analog cTxA 2 (10 Ϫ5 M), 4-Br A23187 (10 Ϫ5 M), or ET-1 (10 Ϫ10 M). In all cases, constriction stabilized within 15 min (Fig. 7A) . In a first set of experiments, indomethacin (10 Ϫ6 M) was subsequently added to the bath. As in the case of ANG II (Fig. 6) , a tendency for indomethacin to vasodilate the preconstricted vessels was observed (Fig. 7B ). This vasodilatory effect was less pronounced than that associated with ANG II (Fig. 6) , and it achieved significance only with the most potent vasoconstrictor ET-1.
In a separate series of experiments, the ability of indomethacin to reverse adenosine-induced vasodilation was examined (Fig. 8, A-C) . After 15-min applica- 
Ϫ4 M]. ADO effectively vasodilated the preconstricted vessels (*P Ͻ 0.05 vs. initial ANG II application), but there were no significant effects of the NOS inhibitors (n ϭ 6-11). B: NOS inhibitors alone tended to induce mild vasoconstriction (*P Ͻ 0.05). n ϭ 6, 9, L-NAME and L-NMMA, respectively. ] i ) response by ADO and bradykinin (BK). A: after baseline recording of the fura 2 signal for 1 min, ADO was added to the bath at 10 Ϫ9 M concentration (8 min) and then removed (2 min). Subsequently, each vessel was exposed to ADO at 10 Ϫ5 M for the same time periods. A small response was observed at each ADO concentration (n ϭ 7). B: after 1 min of recording, BK (10 Ϫ7 M) was added to the bath (10 min) and then removed (2 min). The large response induced by this endothelium-dependent vasodilator is to be contrasted with that induced by ADO. Compare the scale of the ordinates in A and B.
tion of the respective vasoconstrictor, adenosine was added to the bath for 5 min. Significant vasodilation was observed in all cases. Subsequently, indomethacin was introduced along with adenosine for another 5-min period. As in the case of ANG II (Fig. 6) , indomethacin uniformly reversed adenosine-induced vasodilation. In the case of ET-1, an additional period was included to verify the reversibility of this effect on removal of indomethacin from the bath (Fig. 8C) .
A 2 activation during COX inhibition. We previously showed that adenosine constricts OMDVR at low concentration and dilates OMDVR at high concentration and that these actions are mediated by A 1 and A 2 receptors, respectively (31) . To test the hypothesis that exaggerated vasoconstriction of OMDVR by adenosine during COX inhibition in preconstricted vessels (Fig. 8) is accounted for by blockade of A 2 -receptor signaling, we performed two series of experiments. First, we tested the hypothesis that during COX inhibition, adenosine would act as a vasoconstrictor at low concentration, where it typically does so, and at high concentration where A 2 -receptor activation favors vasodilation. At 5-min intervals, in the presence of indomethacin (10 Ϫ6 M), OMDVR were sequentially exposed to adenosine at 10 Ϫ8 and then 10 Ϫ5 M. For maximum sensitivity, vessels that did not exhibit at least 25% constriction in response to 10 Ϫ8 M adenosine were eliminated. As shown in Fig. 9 , in the presence of indomethacin, the concentration-dependent, biphasic effect of adenosine was observed. OMDVR constricted by 10 Ϫ8 M adenosine (baseline internal diameter 12.3 Ϯ 1.6 m) dilated in response to 10 Ϫ5 M adenosine, a concentration at which A 2 receptors should be activated. This finding shows that A 2 receptor-mediated signaling remains during COX inhibition.
In a second series of experiments, OMDVR were preconstricted by ET-1 (10 Ϫ10 M) in the presence of indomethacin (10 Ϫ6 M) and allowed to stabilize for 15 min. Subsequently, to test the ability of A 2 stimulation to induce vasodilation, either adenosine (10 Ϫ5 M, mixed A 1 , A 2 agonist), adenosine (10 Ϫ5 M) ϩ A 1 -receptor antagonist DPCPX (3 ϫ 10 Ϫ8 M), or the A 2 agonist CGS-21680 (10 Ϫ7 M) was added to and then removed from the bath at 5-min intervals. In the presence of indomethacin, ET-1 constricted each group from baseline internal diameters of 12.1 Ϯ 1.6, 11.3 Ϯ 1.0, and 11.3 Ϯ 0.7 m, respectively, to ϳ50% of the original value. When A 1 -receptor stimulation was blocked (DPCPX ϩ adenosine) or absent (CGS-21680), dilation of preconstricted vessels occurred (Fig. 10) . In contrast, as previously observed (Fig. 8C) , mixed A 1 and A 2 stimulation with adenosine resulted in exaggeration of Fig. 6 . Effect of cyclooxygenase (COX) inhibition on ADO-induced vasodilation. A: vessels were preconstricted with ANG II (10 Ϫ9 M, 10 min, n ϭ 9) and then sham exchanged (no significant effect). Subsequently, ADO was added to the bath, inducing significant vasodilation (*P Ͻ 0.05 vs. ANG II preconstriction). B: compared with sham-exchanged time controls (A), ANG II preconstriction (10 Ϫ9 M, 10 min, n ϭ 6) was significantly reversed by indomethacin (Indo; 10 Ϫ6 M, *P Ͻ 0.05 vs. ANG II ϩ Indo). Subsequent addition of ADO during COX blockade was accompanied by significant and reversible vasoconstriction (#P Ͻ 0.05) rather than vasodilation as observed in A. Fig. 7 . Effect of COX inhibition on vasoconstriction by carbocyclic thromboxane A 2 (cTxA 2 ), 4-bromo-calcium ionophore A23187 (4-Br A23187), and endothelin-1 (ET-1). A: baseline diameters of OMDVR were recorded for 1 min after which cTxA 2 (10 Ϫ5 M), 4-Br A23187 (10 Ϫ5 M), or ET-1 (10 Ϫ10 M) was introduced into the bath (n ϭ 6 each). By 15 min, vasoconstriction stabilized in all cases. B: after 15 min of application of cTxA 2 (10 Ϫ5 M, n ϭ 8), 4-Br A23187 (10 Ϫ5 M, n ϭ 7), or ET-1 (10 Ϫ10 M, n ϭ 8), Indo (10 Ϫ6 M) was added to and then removed from the bath at 5-min intervals. In each case, slight reversal of vasoconstriction was observed, but this achieved significance only in the case of ET-1 (*P Ͻ 0.05 Indo vs. ET-1 alone). Some vessels are the same as those in A, but the diameters were recorded only at the end of each period.
vasoconstriction. Thus, in ET-1-constricted vessels, vasodilation through A 2 -receptor activation continues during COX inhibition.
DISCUSSION
In most vascular beds, adenosine is generated during periods of increased oxygen demand or decreased supply to enhance blood flow by inducing local vasodilation. The regional effects of adenosine in the kidney include cortical vasoconstriction, an increase in medullary blood flow, and a reduction of glomerular filtration rate (3, 20, 21) . Presumably, these actions serve to enhance medullary oxygen delivery and to reduce the Fig. 8 . Effect of COX inhibition on vasodilation by ADO. A: OMDVR were preconstricted with cTxA 2 (10 Ϫ5 M, 15 min, n ϭ 8) after which ADO (10 Ϫ5 M, 5 min) was added to the bath, inducing significant dilation (*P Ͻ 0.05 vs. cTxA 2 alone). Subsequently, Indo (10 Ϫ6 M, 5 min) was also added, resulting in reversal of the ADO effect (#P Ͻ 0.05 vs. cTxA 2 ϩ ADO). B: same protocol as in A, except that 4-Br A23187 (10 Ϫ5 M, n ϭ 7) was used to induce vasoconstriction. C: same protocol as in A and B, except that ET-1 (10 Ϫ10 M, n ϭ 8) was used to induce vasoconstriction. Recovery periods were also included to demonstrate reversability of the effects of ADO and Indo. ADO induced vasodilation (*P Ͻ 0.05 vs. ET-1 alone) that was reversed by Indo (#P Ͻ 0.05 vs. ET-1 ϩ ADO). oxygen demand that arises from sodium transport in the thick ascending limb. Consistent with this notion, adenosine infused into the renal interstitium increases both medullary oxygen tension and blood flow (3, 10) . On the basis of these observations, it is reasonable to hypothesize that adenosine produced by the medullary thick ascending limb (mTAL) (5) diffuses to and dilates OM-DVR on the periphery of vascular bundles. Because OM-DVR on the bundle periphery supply the adjacent interbundle region where the mTAL resides, a feedback system would serve to enhance oxygen delivery to the inner stripe of the outer medulla. The possibility that OMDVR participate in such a process is supported by the finding that the mTAL has the capacity to produce adenosine (5) and that A 1 and A 2 receptor mRNA is expressed in OMDVR (14, 31) . We previously demonstrated that A 1 and A 2 adenosine-receptor stimulation on OMDVR favor vasoconstriction and vasodilation, respectively. The A 1 -receptor agonist cyclohexyladenosine constricts OMDVR, and the A 2 -receptor agonist CGS-21680 dilates OMDVR preconstricted by ANG II. Consistent with these observations, adenosine itself constricted OMDVR at low concentrations (10 Ϫ12 to 10 Ϫ8 M) where high-affinity A 1 -receptor effects are expected to dominate but not at high concentrations (10 Ϫ7 to 10 Ϫ5 M) where A 2 receptor-mediated effects should occur (31) . This is the first study of the signaling pathways responsible for OMDVR dilation by adenosine. Before the development of adenosine analogs and antagonists, the observation that adenosine caused an increase in cAMP in some tissues and a decrease in others led to the conclusion that two receptor populations exist (36) . Designated A 1 and A 2 , they were found to interact with adenylate cyclase through inhibitory and stimulatory G proteins, respectively (35) . Stimulation of the highaffinity A 1 receptor results in diminished cAMP levels and vasoconstriction, whereas stimulation of the lower-affinity A 2 receptors increases cAMP levels and causes vasodilation. Some studies have favored other effects of A 2 receptor-subtype stimulation through specific subtypes (A 2a and A 2b ). Cushing et al. (8) found that although adenosine vasodilates coronary arteries via cAMP, the A 2 agonists 5Ј-(N-ethylcarboxamido)adenosine (NECA) and CGS-21680 failed to increase cAMP production. In addition, Martin and Potts (19) demonstrated that NECA and the A 2 agonist N6-cyclopentyladenosine mediated vasodilation of isolated renal arteries and required an intact endothelium. On the basis of the notion that CGS-21680 is more A 2a receptor selective (7), it has been hypothesized that adenosine receptor-signaling mechanisms may be complex, involving agonist interaction with more than one adenylate cyclase-coupled A 2 -receptor subtype. In our hands, both pharmacological manipulations (Figs. 1, 2 , and 4) and direct microassay of cAMP production (Fig.  3) indicate that cAMP is involved in adenosine-induced vasodilation of OMDVR.
With regard to the identity of the diffusible mediators that are generated on adenosine stimulation, we investigated two pathways, NO and prostaglandins. The NO pathway is known to be very important in the modulation of OMDVR vasomotor tone and renal medullary blood flow (21, 26, 37) . It has been shown that acetylcholine and bradykinin vasodilate OMDVR in an NO-dependent fashion and that NOS blockade can be reversed with excess L-arginine. Abluminal application of L-arginine also produces a concentration-dependent dilation of preconstricted OMDVR, favoring a role for constitutive expression of NOS in these vessels (25, 37) . In isolated OMDVR of this study, however, NOS inhibition had no effect on adenosine-induced vasodilation of ANG II-preconstricted vessels (Fig. 4) . Interestingly, however, adenosine did elicit an [Ca 2ϩ ] i response in fura 2-loaded OMDVR at both 10 Ϫ5 and 10
Ϫ9
M. This response was small compared with that generated by the endothelium-dependent vasodilator bradykinin (Fig. 5) . On the basis of this comparison, it seems unlikely that Ca 2ϩ -dependent NOS isoforms are stimulated to a significant degree by adenosine, but it is possible that Ca 2ϩ plays a role in adenosine-induced vasodilation. The small responses in Fig. 5 might represent localized effects within the cytoplasm sufficient to stimulate phospholipases or COX. A less likely explanation is that it is due to sizable responses in a small fraction of the endothelial cells that comprise the OMDVR wall.
In addition to NO, vascular endothelial cells can generate vasodilatory prostaglandins (e.g., prostacyclin), and a role for prostaglandins to modulate regional blood flow within the kidney has been established (26) . Prostaglandin synthesis leads to redistribution of cortical blood flow toward the juxtamedullary region (13, 16) , and blockade of prostaglandin synthesis reduces inner medullary blood flow (17) . Interestingly, in this study, indomethacin reversed constriction of OMDVR, implying a role for vasoconstrictor prostaglandins to mediate constriction by the peptide hormones ANG II and ET-1 (Figs. 5 and 7). Such a role for thromboxanes in ANG II-induced vasoconstriction within the kidney has been described by others (21) .
Despite the tendency of indomethacin to dilate preconstricted OMDVR, its effect in the presence of adenosine was to promote additional vasoconstriction (Figs.  5, 8, and 10 ). This observation supports the conclusion that generation of vasodilatory prostaglandin(s) mediates the dilation of OMDVR by adenosine. The results shown in Figs. 9 and 10 imply that this cannot be explained solely by blockade of A 2 -receptor signaling. An alternate hypothesis is that the apparent effect of vasoconstrictors is enhanced during COX inhibition because arachidonic acid liberated by phospholipase A 2 is metabolized to form other vasoconstrictors by the lipoxygenase or P 450 pathways.
In conclusion, micromolar concentrations of adenosine vasodilate OMDVR in a cAMP-dependent manner. The adenosine response is independent of NOS and does not involve large changes in endothelial cytoplasmic calcium concentration. Nonspecific blockade of COX in OMDVR abrogates vasoconstriction by ANG II and ET-1, implying a role for the generation of prostaglandins in their signaling pathways. In contrast, in the presence of adenosine, COX blockade in preconstricted OMDVR led to vasoconstriction rather than vasodilation, supporting the hypothesis that prostaglandins are involved in vasodilation by adenosine. This work was supported by National Institutes of Health Grants DK-57329 (to E. P. Silldorff), DK-42495, and HL-2220 (to T. L. Pallone).
